New abbreviation here to become acquainted with (PGx) which is pharmacogenics, and one more move in the direction of personalized medicine by big Pharma as the marketing of blockbuster drugs slowly evolves to a new business model with genomic data input becoming a part of the process to bring new drugs to market. Clinical trials are now also more frequently relying on genomic data to help increase the speed and accuracy of data produced as well. BD
NEW YORK (GenomeWeb News) - Eli Lilly has hired the pharmacogenetic consultancy firm Cabernet Pharmaceuticals to help it make PGx-guided drug development decisions.
“Under the agreement, Cabernet consultants will join clinical development teams at Lilly to assist in applying pharmacogenetics to selected development projects,” Cabernet and Lilly said in a statement.
However, both Cabernet and Lilly are keeping a tight lid on which specific drug programs they are applying PGx strategies.
“Cabernet provides highly trained individuals that complement our existing work force,” Stephen Eck, Lilly’s VP of translational medicine and pharmacogenomics, told Pharmacogenomics Reporter this week. “The current arrangement allows us to rapidly expand our capability and capacity while creating a more flexible cost base.”
While PGx has often been shunned by Pharma for being the poison pill to its blockbuster strategy, industry observers have long held that drug companies will eventually warm to pharmacogenetics strategies in order to reduce attrition rates and run more cost-effective clinical trials. Several pharmas, like Pfizer, Bristol-Myers Squibb, Novartis, and even Lilly, have tepidly acknowledged that they are experimenting with PGx internally, while still keeping an eye on the blockbuster homerun.
http://www.genomeweb.com/issues/news/150539-1.html
0 comments :
Post a Comment